ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 92

Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls

Barbara Dreo1, Barbara Prietl 2, Selina Kofler 2, Harald Sourij 2, Angelika Lackner 1, Florentine Moazedi-Fuerst 1, Monica D'Orazio 1, Martin Stradner 1, Winfried Graninger 1 and Hans-Peter Brezinschek 1, 1Department of Internal Medicine/Division of Rheumatology and Immunology, Graz, Austria, 22CBmed GmbH – Center for Biomarker Research in Medicine, Graz, Austria

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: immune checkpoint molecules and rheumatoide arthritis, T regulatory subsets

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: T regulatory cells (Treg) play a crucial role in the regulation of the immune response and therefore are of utmost interest when studying autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Therefore, targeting specific Treg markers in therapy is now widely discussed. Expression of T cell immunoglobulin 3 (TIM-3) is associated with an enhanced immune suppression and is currently discussed as target in cancer therapy. Fc receptor-like protein 3 (FCLR-3), which regulates Treg proliferation, was shown to be associated with the susceptibility in juvenile RA. Other surface markers, like CD161 enable Treg to produce IL-17A, IFNγ and IL-2, hence promoting inflammation. The aim of this study was to distinguish between RA and SLE using anti-and pro-inflammatory cell markers.

Methods: Peripheral blood samples from 66 patients suffering from RA (mean ± SD; age 60 ± 10 years, female ratio: 0.68, disease duration 18 ± 14 years), 40 SLE patients (age 42 ± 13 years, female ratio 0.85, disease duration 11 ± 13 years) and 72 age-matched healthy participants (age 46 ± 17 years, female ratio 0.68) were drawn over a sampling period of two years. Freshly isolated PBMCs were stained and Treg subsets were identified by the expression of CD25, CD127, FoxP3, CD45RA and CD15 on the surface of CD3+CD4+ T cells. CD25+CD127+CD45– Treg were further subclassified by the expression of TIM-3 (CD366) and FCLR-3 (CD307c). CD161 was used to identify Th17 type Treg (CD15S–CD161–) and transitional Treg (CD15S–CD161–). All cytometric measurements were performed using a standardized BD LSR Fortessa platform.

Results: Transitional Treg (CD15S–CD161–) were significantly higher (p < 0.001) in RA patients compared to the SLE and healthy cohort (40.5 ± 13.4% vs. 28.7 ± 9.6% and 29.7 ± 9.4% respectively). However, differences in the CD161+ Th17 type Treg population could not be detected. Treg expressing TIM-3 were higher in both RA and SLE patients compared to healthy controls (2.8 ± 2.3%, p = 0.0105 and 2,.6 ± 1.6%, p = 0.0031 vs. 0.8 ± 0.7% respectively), but did not differ between the rheumatic diseases. On the other hand, FCLR-3 positive Treg distinguished RA and SLE patients (17.8 ± 13.3 vs. 25.3 ± 13.1%, p = 0.0036), as well as SLE patients from healthy controls (16.8 ± 12.9%, p = 0.0112). All findings were not correlated with the disease activity of RA or SLE patients.

Conclusion: Expression of the negative immune checkpoint molecules TIM-3 and FCRL-3 not only distinguish healthy controls from patients suffering from RA or SLE but can be used to differentiate between different autoimmune diseases. These findings indicate that the regulation of the immune response in RA and SLE is triggered by Treg, yet the activation of different Treg subset is disease-specific.


Disclosure: B. Dreo, None; B. Prietl, None; S. Kofler, None; H. Sourij, None; A. Lackner, None; F. Moazedi-Fuerst, None; M. D'Orazio, None; M. Stradner, None; W. Graninger, None; H. Brezinschek, None.

To cite this abstract in AMA style:

Dreo B, Prietl B, Kofler S, Sourij H, Lackner A, Moazedi-Fuerst F, D'Orazio M, Stradner M, Graninger W, Brezinschek H. Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/negative-immune-checkpoint-molecules-on-t-regulator-cells-distinguish-ra-sle-and-healthy-controls/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/negative-immune-checkpoint-molecules-on-t-regulator-cells-distinguish-ra-sle-and-healthy-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology